New Drug Approvals

Recilisib Sodium, EX-RAD June 16, 2016 - (0)

Recilisib Sodium Phase I C16H12ClNaO4S Molecular Weight: 358.771849 g/mol A protein kinase inhibitor potentially for the treatment of acute radiation syndrome. sodium;4-[(E)-2-[(4-chlorophenyl)methylsulfonyl]ethenyl]benzoate Onc-01210; ON-01210.Na, Ex-RAD; ON 01210.Na; ON-01210; ON-01210-Na; Recilisib CAS No. 334969-03-8(free) CAS 922139-31-9(Recilisib sodium) Benzoic acid, 4-[(1E)-2-[[(4-chlorophenyl)methyl]sulfonyl]ethenyl]-, sodium salt (1:1) Onconova Therapeutics Inc, Univ Temple INNOVATOR Stephen C Cosenza, Lawrence Helson,Premkumar E Reddy, Ramana M V […]
Amneal Pharma’s, 4,5-Dihydro-1H-pyrazolo[3,4-d]pyrimidine containing phenothiazines as antitubercular agents June 15, 2016 - (0)
AMG 900, An aurora kinase (ARK) inhibitor potentially for the treatment of leukemia and solid tumours June 15, 2016 - (0)
GSK 1070916 For Advanced solid tumor June 15, 2016 - (0)
Maralixibat Chloride, ماراليكسيبات كلوريد , 氯马昔巴特 , Мараликсибата хлорид June 15, 2016 - (0)

Mobile Site | Full Site